Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(04): 495-501
DOI: 10.4103/ijmpo.ijmpo_200_16
Original Article

Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single‑center Data

Tejinder Kataria
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Trinanjan Basu
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Deepak Gupta
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Shikha Goyal
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Shahida Nasreen
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Shyam S Bisht
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Ashu Abhishek
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Susovan Banerjee
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Kushal Narang
Division of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana, India
,
Ajaya N Jha
Division of Neurosurgery, Medanta The Medicity, Gurgaon, Haryana, India
,
Ishani Mohapatra
Department of Pathology, Medanta The Medicity, Gurgaon, Haryana, India
,
Jayesh A Modi
Department of Radiology and Imaging, Medanta The Medicity, Gurgaon, Haryana, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Objective: To evaluate early clinical outcome for anaplastic gliomas (AG) treated in the era of modulated radiotherapy (RT) and concurrent plus adjuvant temozolomide (TMZ) in an Indian setting. Materials and Methods: Fifty-three patients with AGs treated with modulated RT and concurrent (95%) and adjuvant TMZ (90%) were analyzed. About 80% of patients had Karnofsky performance status (KPS) at least 90 with 30% seizure at presentation. Postoperative magnetic resonance imaging was available in 65% cases and RT dose was 60 Gy in 30 fractions. First posttreatment imaging was performed at 1 month and then at 3 and 6 months post-RT and then every 3 months. Kaplan–Meier analysis was used to estimate disease-free survival (DFS) and overall survival (OS), and analysis was done using SPSS version 18.0. Results: With median follow-up of 25 months, 2-year DFS and OS were 75% and 88%. There were only 5% symptomatic central nerves system and 8% symptomatic hematological toxicities. At the 1st evaluation, 30.4% hadcomplete response (CR), at 3 months 40%, and at 6 months 43%. At 6 months, only 4% had progressive disease. Forty-six patients were evaluable till the last follow-up with and 55% had stable to CR. On univariate analysis for DFS, KPS at presentation >90 (P = 0.001) and response at 6 months (P = 0.02) were significant and for OS KPS at presentation (P = 0.004) alone. Conclusion: Modulated RT with TMZ among Grade III glioma patients resulted in minimum treatment-related toxicities and encouraging survival. Molecular prognostic markers will determine most favorable groups in future.

Keywords

Anaplastic glioma - modulated radiotherapy - survival - temozolomide


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used forcommercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 GLOBOCAN 2012 Ver. 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer; 2013. Available from: http://www.globocan.iarc.fr. [Last accessed on 2014 Feb 19].
  • 2 Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: Final report. Int J Radiat Oncol Biol Phys 1979;5:1733-40.
  • 3 Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30 6 Suppl 19:10-4.
  • 4 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
  • 5 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803-20.
  • 6 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
  • 7 Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
  • 8 Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 2013;31:337-43.
  • 9 van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344-50.
  • 10 Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016;18:1529-37.
  • 11 Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, et al. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys 2015;91:268-76.
  • 12 Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol 2006;24:4746-53.
  • 13 Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
  • 14 Walker MD, Alexander E Jr., Hunt WE, MacCarty CS, Mahaley MS Jr., Mealey J Jr., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-43.
  • 15 Stenning SP, Freedman LS, Bleehen NM. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 1987;56:89-90.
  • 16 Lonardi S, Tosoni A, Brandes AA. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 2005;31:79-89.
  • 17 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011;13:649-59.
  • 18 Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol 2014;37:177-81.
  • 19 Wick W, Wiestler B, Platten M. Treatment of anaplastic glioma. Cancer Treat Res 2015;163:89-101.
  • 20 Lassman AB. Procarbazine, lomustine and vincristine or temozolomide: Which is the better regimen? CNS Oncol 2015;4:341-6.
  • 21 Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2014;(5):CD007104.
  • 22 Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-80.
  • 23 Yu T, Kang HC, Lim DH, Kim IH, Chung WK, Suh CO, et al. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: The Korean Radiation Oncology Group study 13-12. J Neurooncol 2015;121:531-9.
  • 24 Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013;(4):CD007415.
  • 25 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH (CATNON). Identifier: NCT00626990. Available from: htttp://www. ClinicalTrials.gov. [Last accessed 2017 Jul 26].
  • 26 Jaeckle K, Vogelbaum M, Ballman KV, et al. CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis of Patients Treated on the Original Protocol Design. Neurology 2016;86 Suppl 16: Abstract PL02.005.
  • 27 Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: Acomparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol 2016;127:165-71.
  • 28 Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, et al. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: A retrospective review within the era of temozolomide. J Neurooncol 2013;113:305-11.
  • 29 Rogne SG, Konglund A, Scheie D, Helseth E, Meling TR. Anaplastic astrocytomas: Survival and prognostic factors in a surgical series. Acta Neurochir (Wien) 2014;156:1053-61.
  • 30 Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA. Prognostic factors for anaplastic astrocytomas. J Neurooncol 2007;81:295-303.
  • 31 Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
  • 32 Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, et al. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol 2014;120:85-93.
  • 33 Rajmohan KS, Sugur HS, Shwetha SD, Ramesh A, Thennarasu K, Pandey P, et al. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: Applying the 'integrated' diagnosis approach. J Clin Pathol 2016;69:686-94.
  • 34 Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499-508.
  • 35 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.